Cytomegalovirus treatment options in immunocompromised patients

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 8, 2001, Pages 1247-1257

  Khare, M D ^a   Sharland, M ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

AIDS; Benzimidazole; Bone marrow transplant; Cidofovir; CMV; Fomivirsen; Foscarnet; Ganciclovir; Immunocompromised; Methylenecyclopropane analogues; Solid organ transplant; Valganciclovir

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; AZATHIOPRINE; BENZIMIDAZOLE; CIDOFOVIR; CYCLOPROPANE DERIVATIVE; CYCLOSPORIN A; DIDANOSINE; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; GENTAMICIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; NUCLEOSIDE ANALOG; PENTAMIDINE; PROBENECID; VALACICLOVIR; VALGANCICLOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANOREXIA; ANTIBIOTIC RESISTANCE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BRAIN DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; EPIDEMIC; EYE DISEASE; FEVER; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFANT; MALAISE; MENTAL DISEASE; METABOLIC DISORDER; MORBIDITY; MORTALITY; MOUSE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RASH; RETINITIS; REVIEW; SEIZURE; SYMPTOMATOLOGY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 0034878967     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.8.1247     Document Type: Review

References (95)

1. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment
2. Cytomegalovirus infection in patients with AIDS
3. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation
4. Comparison of cytomegalovirus antigenemia and culture assays in patients on and off antiviral therapy
5. Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leukocytes of immunocompromised patients
6. Time to detection of cytomegalovirus (CMV) DNA in blood leukocytes is a predictor for the development of CMV disease in CMV-seronegative recipients of allografts from CMV-seropositive donors following liver transplantation
7. Quantitation of cytomegalovirus in the blood of liver transplant recipients
8. Diagnosis of cytomegalovirus (CMV) disease in renal allograft recipients: The role of semiquantitative polymerase chain reaction (PCR)
9. Correlation of cytomegalovirus DNA levels with response to antiviral therapy in cardiac and renal allograft recipients
10. COBAS AMPLICOR: Fully automated RNA and DNA amplification and detection system for routine diagnostic PCR
11. Evaluation of automated COBAS AMPLICOR PCR system for detection of several infectious agents and its impact on laboratory management
12. Human cytomegalovirus (HCMV) late-mRNA detection in peripheral blood of AIDS patients: Diagnostic value for HCMV disease compared with those of viral culture and HCMV DNA detection
13. Circulating immediate-early mRNA in patients with cytomegalovirus infections after solid organ transplantation
14. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells
15. Activity of 9-(1,3-dihydroxy-2-propoxymethyl) guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses
16. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients
17. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections
18. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function
19. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl) guanine and acyclovir in herpes simplex virus-infected and uninfected cells
20. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl) ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus
21. Human pharmacokinetics of the antiviral drug DHPG
22. Ganciclovir transfer by human placenta and its effects on rat fetal cells
23. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: A Phase I/II study
24. Steady-state relative bioavailability of three oral ganciclovir dosage regimens delivering 6,000 mg/day in patients with human immunodeficiency virus
25. Ganciclovir treatment of cytomegalovirus infection of the gastrointestinal tract after marrow transplantation
26. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin
27. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
28. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
29. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation
30. Antimicrobial strategies in the care of organ transplant recipients
31. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
32. Ganciclovir (GCV) Treatment of Symptomatic Congenital Cytomegalovirus (CMV) Infections: Results of Phase III Randomised trial
33. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2- propoxymethyl)guanine in patients with AIDS and other immunodeficiencies
34. Treatment of cytomegalovirus retinopathy with ganciclovir
35. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus
36. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS
37. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis
38. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis
39. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant
40. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant
41. Ganciclovir treatment of
42. Ganciclovir
43. Central nervous system side effects of ganciclovir
44. Cytomegalovirus infection in orthotopic liver transplantation
45. Ganciclovir-associated hypercalcemia in a renal transplant patient
46. Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro
47. Efficacy of ganciclovir in combination with zidovudine against cytomegalovirus in vitro and in vivo
48. The Cys607→Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients
49. Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease
50. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis
51. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes
52. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV- seropositive subjects
53. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers
54. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
55. The effect of pyrophosphate analogues on influenza virus RNA polymerase and influenza virus multiplication
56. Antiviral effects of phosphonoformate (PFA, foscarnet sodium)
57. Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients
58. Foscarnet penetrates the blood-brain barrier: Rationale for therapy of cytomegalovirus encephalitis
59. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis
60. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
61. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
62. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS
63. Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: A randomized comparison
64. Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. A case report and review of the literature
65. Ganciclovir/foscarnet for cytomegalovirus meningoencephalitis in AIDS
66. Acute renal failure induced by foscarnet: 4 cases
67. Foscarnet nephrotoxicity: Mechanism, incidence and prevention
68. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism
69. Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection
70. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease
71. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient
72. Cidofovir in the treatment of cytomegaloviral disease
73. Clinical uses of cidofovir
74. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial
75. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS
76. Anticytomegaloviral activity and safety of cidofovir in patients with and immunodeficiency virus infection and cytomegalovirus viruria
77. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: The HPMPC Peripheral Cytomegalovirus Retinitis Trial
78. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial
79. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine
80. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
81. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation
82. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts
83. Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation
84. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease
85. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA
86. Fomivirsen safety and efficacy in the treatment of CMB retinitis: A Phase 3, controlled multicenter study comparing immediate versus delayed treatment
87. Cytomegalovirus infections following renal transplantation-effects on antiviral prophylaxis: A report of the North American Pediatric Renal Transplant Cooperative Study
88. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients
89. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial
90. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection
91. First 'antisense' drug will treat CMV retinitis
92. In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections
93. Cytomegalovirus in transplantation: New developments
94. Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation
95. Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence